SMT202100541T1 - Combinazioni e loro usi - Google Patents

Combinazioni e loro usi

Info

Publication number
SMT202100541T1
SMT202100541T1 SM20210541T SMT202100541T SMT202100541T1 SM T202100541 T1 SMT202100541 T1 SM T202100541T1 SM 20210541 T SM20210541 T SM 20210541T SM T202100541 T SMT202100541 T SM T202100541T SM T202100541 T1 SMT202100541 T1 SM T202100541T1
Authority
SM
San Marino
Prior art keywords
combinations
Prior art date
Application number
SM20210541T
Other languages
English (en)
Italian (it)
Inventor
Jan Endell
Rainer Boxhammer
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of SMT202100541T1 publication Critical patent/SMT202100541T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
SM20210541T 2015-08-21 2016-08-18 Combinazioni e loro usi SMT202100541T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof
EP16756997.9A EP3337506B1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof

Publications (1)

Publication Number Publication Date
SMT202100541T1 true SMT202100541T1 (it) 2021-11-12

Family

ID=54010888

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20210541T SMT202100541T1 (it) 2015-08-21 2016-08-18 Combinazioni e loro usi

Country Status (23)

Country Link
US (3) US11224654B2 (enExample)
EP (2) EP3954388A1 (enExample)
JP (4) JP6862422B2 (enExample)
KR (2) KR102786010B1 (enExample)
CN (2) CN107921129B (enExample)
AU (3) AU2016311136B2 (enExample)
CA (1) CA2995738A1 (enExample)
CY (1) CY1124706T1 (enExample)
DK (1) DK3337506T3 (enExample)
ES (1) ES2891336T3 (enExample)
HR (1) HRP20211291T1 (enExample)
HU (1) HUE056408T2 (enExample)
IL (2) IL257345B2 (enExample)
LT (1) LT3337506T (enExample)
MX (2) MX392561B (enExample)
PL (1) PL3337506T3 (enExample)
PT (1) PT3337506T (enExample)
RS (1) RS62260B1 (enExample)
RU (1) RU2767063C2 (enExample)
SI (1) SI3337506T1 (enExample)
SM (1) SMT202100541T1 (enExample)
WO (1) WO2017032679A1 (enExample)
ZA (1) ZA201801052B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
BR112019025034A2 (pt) 2017-05-31 2020-06-30 Morphosys Ag combinação
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
PH12022551021A1 (en) * 2019-10-31 2023-03-06 Morphosys Ag Sequential anti-cd19 therapy
WO2022115762A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
US20230357392A1 (en) * 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
KR100785363B1 (ko) 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
WO2002022212A2 (en) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
JP5215180B2 (ja) 2005-06-20 2013-06-19 メダレックス インコーポレーティッド Ｃｄ１９抗体およびその使用法
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ES2402591T3 (es) 2006-08-14 2013-05-07 Xencor Inc. Anticuerpos optimizados que seleccionan como diana CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2659517T3 (es) 2007-05-30 2018-03-16 Xencor, Inc. Métodos y composiciones para inhibir células que expresan CD32B
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
AU2010263272C1 (en) 2009-06-24 2016-02-11 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
US8840888B2 (en) * 2009-10-27 2014-09-23 Micromet Ag Dosage regimen for administering a CD19XCD3 bispecific antibody
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US9272052B2 (en) * 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PT2744826T (pt) 2011-08-16 2022-05-19 Morphosys Ag Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina
KR20140064873A (ko) 2011-08-16 2014-05-28 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
CA2890105C (en) 2012-11-01 2023-03-21 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
MX356112B (es) 2013-02-15 2018-05-15 3M Innovative Properties Co Sistema y metodo para elaborar medios de filtracion plegados.
US20170137516A1 (en) 2014-06-16 2017-05-18 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
SMT201900647T1 (it) 2015-05-26 2020-01-14 Morphosys Ag Combinazione di un anticorpo anti-cd19 e un inibitore della tirosina chinasi di bruton e suoi usi
WO2017032679A1 (en) 2015-08-21 2017-03-02 Morphosys Ag Combinations and uses thereof
LT3916392T (lt) 2016-05-30 2024-08-26 Incyte Corporation Pacientų gydymo anti-cd19 terapinės naudos prognozavimo būdai
SG10201912369QA (en) 2016-06-27 2020-02-27 Morphosys Ag Anti-cd19 antibody formulations
AU2017348624B2 (en) 2016-10-28 2024-09-26 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
BR112019025034A2 (pt) 2017-05-31 2020-06-30 Morphosys Ag combinação
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
PH12022551021A1 (en) 2019-10-31 2023-03-06 Morphosys Ag Sequential anti-cd19 therapy
IL292181A (en) 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
TWI883067B (zh) 2019-10-31 2025-05-11 美商英塞特公司 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法
US20230014026A1 (en) 2020-06-22 2023-01-19 Morphosys Ag Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint
WO2022115762A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
IL303384A (en) 2020-12-04 2023-08-01 Morphosys Ag Anti-CD19 combination therapy
US20230357392A1 (en) 2021-12-22 2023-11-09 Morphosys Ag Treatment Paradigm for an Anti-CD19 Antibody Therapy

Also Published As

Publication number Publication date
MX2018002241A (es) 2018-03-23
JP2025131697A (ja) 2025-09-09
KR20240052084A (ko) 2024-04-22
CY1124706T1 (el) 2022-07-22
AU2016311136A1 (en) 2018-03-01
RU2767063C2 (ru) 2022-03-16
BR112018003263A2 (pt) 2018-09-25
WO2017032679A1 (en) 2017-03-02
DK3337506T3 (da) 2021-09-06
CN115054697A (zh) 2022-09-16
MX2022006154A (es) 2022-10-07
EP3337506A1 (en) 2018-06-27
EP3954388A1 (en) 2022-02-16
CA2995738A1 (en) 2017-03-02
US12194095B2 (en) 2025-01-14
IL297057A (en) 2022-12-01
CN107921129B (zh) 2022-05-27
US11224654B2 (en) 2022-01-18
RU2018107929A3 (enExample) 2020-01-14
CN107921129A (zh) 2018-04-17
US20220088197A1 (en) 2022-03-24
KR102786010B1 (ko) 2025-03-26
HUE056408T2 (hu) 2022-02-28
MX392561B (es) 2025-03-24
LT3337506T (lt) 2021-10-11
JP2018523685A (ja) 2018-08-23
KR20180042335A (ko) 2018-04-25
ZA201801052B (en) 2021-05-26
PT3337506T (pt) 2021-09-24
IL297057B1 (en) 2025-07-01
US20180228893A1 (en) 2018-08-16
JP2023093495A (ja) 2023-07-04
HK1247122A1 (zh) 2018-09-21
JP6862422B2 (ja) 2021-04-21
AU2024202109A1 (en) 2024-05-02
PL3337506T3 (pl) 2022-01-03
CN115054697B (zh) 2024-06-11
JP2021113194A (ja) 2021-08-05
HRP20211291T1 (hr) 2021-12-10
ES2891336T3 (es) 2022-01-27
IL257345B (en) 2022-11-01
EP3337506B1 (en) 2021-07-21
IL297057B2 (en) 2025-11-01
IL257345B2 (en) 2023-03-01
US20250195646A1 (en) 2025-06-19
AU2016311136B2 (en) 2022-02-17
AU2022202800B2 (en) 2024-01-04
NZ739706A (en) 2025-02-28
IL257345A (en) 2018-03-29
SI3337506T1 (sl) 2021-12-31
RS62260B1 (sr) 2021-09-30
RU2018107929A (ru) 2019-09-23
AU2022202800A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
SG11201706029VA (en) Anti-senescence compounds and uses thereof
HUE044571T2 (hu) Módosított ciklopentapeptidek és alkalmazásaik
IL297057B2 (en) Conjunctions and their uses
GB201603311D0 (en) New uses and methods
ZA201705456B (en) Benzoxaborole compounds and uses thereof
GB201612858D0 (en) New uses and methods
GB201504763D0 (en) Compounds and uses
GB201507753D0 (en) New compounds and uses
IL264473A (en) GPR156 variants and their uses
GB2548839B (en) New uses and methods
IL254241A0 (en) Etv2 and its uses
GB201517786D0 (en) Methods and materials
IL253459A0 (en) Isoergoline compounds and their uses
GB201718875D0 (en) Autophagy-inhibiting compounds and uses thereof
GB2545167B (en) Cloches and use thereof
GB2543375B (en) Compounds and their uses
GB201500278D0 (en) Novel combination and use
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning
GB201507752D0 (en) New compounds and uses
GB201512216D0 (en) Agents uses and methods
PT2923578T (pt) Método para a produção de um produto alimentar